Basic Science

Increased Dietary Intake of Vitamin A Promotes Aortic Valve Calcification In Vivo

Danielle J. Huk, Harriet L. Hammond, Hiroyuki Kegechika, Joy Lincoln
https://doi.org/10.1161/ATVBAHA.112.300388
Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33:285-293
Originally published January 16, 2013

Jump to

Abstract

Objective—Calcific aortic valve disease (CAVD) is a major public health problem with no effective treatment available other than surgery. We previously showed that mature heart valves calcify in response to retinoic acid (RA) treatment through downregulation of the SRY transcription factor Sox9. In this study, we investigated the effects of excess vitamin A and its metabolite RA on heart valve structure and function in vivo and examined the molecular mechanisms of RA signaling during the calcification process in vitro.

Methods and Results—Using a combination of approaches, we defined calcific aortic valve disease pathogenesis in mice fed 200 IU/g and 20 IU/g of retinyl palmitate for 12 months at molecular, cellular, and functional levels. We show that mice fed excess vitamin A develop aortic valve stenosis and leaflet calcification associated with increased expression of osteogenic genes and decreased expression of cartilaginous markers. Using a pharmacological approach, we show that RA-mediated Sox9 repression and calcification is regulated by classical RA signaling and requires both RA and retinoid X receptors.

Conclusion—Our studies demonstrate that excess vitamin A dietary intake promotes heart valve calcification in vivo. Therefore suggesting that hypervitaminosis A could serve as a new risk factor of calcific aortic valve disease in the human population.

Introduction

Calcific aortic valve disease (CAVD) is the most prevalent valvular disorder and a major contributor to adult cardiac pathology, affecting nearly 30% of adults aged >65 years.1 Healthy mature aortic valve cusps are composed of 3 stratified layers of extracellular matrix (ECM), and several proteins within these layers share molecular characteristics with cartilage including expression of type II collagen (col2a1).2 In contrast, calcified valves are characterized by alterations in ECM stratification, formation of calcific nodules, and increased expression of osteogenic genes including Spp1 and Runx2.3–5 Collectively, these abnormal changes alter the biomechanics of the valve leading to less supple and more stiffened, or stenotic valve cusps.2 At present, valve replacement surgery is the only effective treatment for aortic stenosis and CAVD, and no medical therapies exist to prevent disease progression.6 Despite the clinical significance, the underlying mechanisms that promote abnormal bone-like processes in the valves remain largely unknown. Over the past several years, a number of clinical, genetic, and anatomic risk factors for CAVD have been identified1,7,8 with influence from the environment and habitual lifestyles. Understanding the contribution of these risk factors to the pathogenesis of CAVD has been greatly improved by studies using mouse models,9–14 including hypercholestrolemic diets previously shown to promote aortic valve disease and CAVD onset in vivo.10,15

Retinoic acid (RA) is the active metabolite of vitamin A (retinol) that is supplied to the body from dietary sources largely in the form of carotenoids.16 Once in the circulation and target tissues, active retinoids function as signaling molecules to specify cell identities and control gene expression.17 RA signals through specific nuclear receptors, including the RA receptor (RAR) and retinoid X receptor (RXR) families that each consist of 3 isoforms: α(a), β(b), and γ(g).18 Signaling through these receptors is involved in many key cellular processes, including cell differentiation, cell cycle control, cell growth, and cellular responses to injury, and has been implicated in the pathogenesis of obesity, diabetes mellitus, and cardiovascular disease.19 The most fundamental mechanism of action of retinoids is through transcriptional regulation of RA responsive nuclear receptors, which is dependent on the formation of dimers. RXR can signal as a homodimer or act as a heterodimeric partner for other nuclear receptors, such as RAR or vitamin D receptors. These complexes then bind to specific response elements including RA response elements located in enhancer regions of target genes to modulate positive and negative function.18

In the heart, genetic and pharmacological approaches to add excess or remove RA in the embryo have revealed essential roles during cardiogenesis. Alterations in RA signaling in several animal model systems recapitulate phenotypes associated with human congenital heart defects, including DiGeorge Syndrome,20,21 transposition of the great arteries,22 ventricular septal defects, persistent truncus arteriosus, double outlet right ventricle,23 hypoplastic ventricular chambers,24 and tetralogy of fallot.25 Defects of the outflow tract are largely attributed to the established roles that RA signaling plays in cardiac neural crest and second heart field cell lineages,26–28 whereas hypoplastic ventricular phenotypes observed in RA mutant mice24,29 have been reported to be the result of altered signaling in nonmyocyte cell lineages,30 including cardiac progenitors31,32 and epicardially derived cells.33–35 In addition to these structures, endocardial cushion abnormalities in the outflow tract and atrioventricular regions are apparent in mice depleted of RXRα23 and RALDH2,36 therefore suggesting a role in early valve formation. Because of premature lethality of these mice, the role of RA on valve maturation could not be examined; however, previous work from our laboratory suggests that high RA signaling promotes abnormal changes in the composition of connective tissue within the mature valve leaflets leading to calcification in vitro.37 We further showed that RA-induced calcification is mediated through repression of Sox9, an SRY transcription factor previously shown to promote cartilage-like phenotypes and prevent bone-like processes in healthy valves, similar to its role in the skeletal system.38

The importance of tightly regulated RA signaling on heart development in the embryo has been extensively examined; however, the effects of altered retinoid activity on cardiac structure and function after birth remain largely unknown. On the basis of our previous observations identifying a role for RA in regulating heart valve connective tissue homeostasis, the goal of this current study was to determine the effects of excess vitamin A and RA signaling on valve structure and function in vivo and examine the molecular mechanisms of RA signaling on Sox9 during this process. Our findings show that increased dietary intake of retinyl palmitate in mice at levels previously shown to induce hypervitaminosis A leads to aortic valve stenosis associated with leaflet calcification. Using an established explant system, we describe that RA-mediated calcification via repression of Sox9 requires both RAR and RXR function in vitro. This decrease in Sox9 is associated with increased expression of the osteogenic target gene Spp1 and downregulation of the cartilaginous collagen type, Col2a1,39 therefore suggesting that in mature heart valves, high RA signaling as a result of excess dietary vitamin A intake represses Sox9 and promotes formation of bone-like calcific nodules at the expense of healthy cartilaginous connective tissue. Together, these observations could provide insights into a previously unappreciated risk factor of CAVD related to increased intake of vitamin A derivatives in the human population.

Materials and Methods

Wild-type C57BL/6J mice were fed either regular chow mix containing 20 IU/g of retinol as retinyl palmitate (Harlan, TD.93160) or a modified excess vitamin A chow containing 200 IU/g retinyl palmitate (Harlan, TD.110146) for a period of 12 months and subjected to echocardiography as described.40 After functional analysis, RNA was extracted from aortic valves or whole hearts and cDNA generated for quantitative real-time polymerase chain reaction as described.37 Alternatively, whole hearts were fixed and sectioned for histological staining as described.40 For in vitro studies, postnatal mouse or embryonic day (E)10 chick mitral and aortic valve explants were treated with ATRA (Sigma, 1 µmol/L), 9-cis-RA (Enzo, 1 µmol/L), LE540 (100 µmol/L), PA452 (100 µmol/L), AM580 (Tocris Bioscience, 1 µmol/L), adapalene (Tocris Bioscience, 10 µmol/L), or dimethyl sulfoxide (DMSO; 0.001% final concentration) for 48 hours. Explants were then mounted on glass slides and fixed for histological staining, or RNA was extracted for microarray analysis using an Affymetrix Mouse GeneST Array. For a full description of materials and methods see online-only Data Supplement.

Results

Long-Term Excess Dietary Vitamin A Promotes Aortic Valve Stenosis and Calcification

Our previous studies have shown that short-term (48 hours) all-trans RA (ATRA) treatment of murine heart valve explants in vitro promotes calcific phenotypes.37 To expand these studies and determine the long-term effects of excess retinol exposure in vivo, C57BL/6J wild-type mice were fed either a control diet containing 20 IU/g of retinol as retinyl palmitate from the time of weaning (4 weeks) or a modified diet containing excess vitamin A (200 IU/g retinyl palmitate). Mice fed these levels of dietary vitamin A intake have previously been shown to serve as models for hypervitaminosis A.41–44 After 12 months of dietary intake, mice were subjected to histological, molecular, and functional analysis. To examine calcium deposition in aortic valve leaflets, von Kossa staining was performed on tissue sections collected from 13-month-old mice fed control (Figure 1A) or the excess vitamin A (Figure 1B) diet. As shown in Figure 1C, mice fed excess vitamin A show significantly greater von Kossa reactivity (0.39±0.04%) compared with controls (4.29±0.41%), indicative of calcification. At the molecular level, increased RAR-β (Rarb) expression confirms activation of RAR/RXR-mediated signaling45 in the excess vitamin A experimental group. In addition to changes in RARb, expression of Sox9, Col2a1, Runx2, bone γ-carboxyglutamic acid-containing protein (Bglap), and type I collagen (Col1a1) are all increased in animals after long-term exposure to excess dietary vitamin A (Figure 1D), consistent with ongoing calcification processes.3,5,46 Functional analysis by echocardiography reveals significant increases in aortic valve peak pressure gradient (Figure 1E) and velocity (Figures 1F–1H) during ventricular systole in mice fed with excess vitamin A diet (n=6), suggesting aortic valve stenosis. These data suggest that long-term exposure to excess dietary vitamin A in mice recapitulates CAVD phenotypes at cellular, molecular, and functional levels.

Figure 1.
Figure 1.

Excess dietary vitamin A promotes heart valve calcification phenotypes in mice. C57BL/6J wild-type mice were fed either a control diet containing 20 IU/g retinyl palmitate or an excess vitamin A diet containing 200 IU/g over a period of 12 months. A and B, von Kossa reactivity indicates calcific nodule formation (arrows) in aortic valves from mice fed control (A), or an excess vitamin A (B) diet. C, Quantification of von Kossa as a percentage of total area defined by Alcian blue staining (n=3). D, Quantitative polymerase chain reaction to show fold changes in gene expression in aortic valves from mice fed an excess vitamin A diet compared with controls (n=3). E–H, Echocardiography and Doppler flow analysis to show aortic valve peak pressure gradient (E) and peak velocity (F) in mice fed excess vitamin A. G and H, Representative Doppler profiles of aortic outflow velocity for mice subjected to control (G) and excess vitamin A (H) diets (n=6). Blue vertical line indicates measurements taken. Note changes in axis scale. *P<0.05 over control.

RA-Mediated Calcification Requires Activity of Both RAR and RXR

Findings from in vivo studies in mice (Figure 1) and our previously published in vitro work37 support the hypothesis that increased RA signaling promotes heart valve calcification. To further delineate this and determine the molecular mechanisms required for this process, the approximate absolute transcript number of the RAR and RXR isoforms were examined in postnatal mouse aortic and mitral valves, as well as comparable stages in the chicken (embryonic [E] day 10) (Figure 2). In mouse valves, comparable levels of RA receptor isoforms are identified in mitral and aortic valves, with RARα (RARa) being most highly expressed (Figure 2A). In contrast, RARb and RARγ (RARg) are most predominant in chicken valves (Figure 2B). Because RXRa and RXRb isoforms have not been reported in the avian system, they were not included in this analysis.

Figure 2.
Figure 2.

Retinoic acid receptor isoforms are highly expressed in mouse and chicken aortic and mitral valves. Quantitative real-time polymerase chain reaction to show approximate absolute transcript numbers of various RAR and retinoid X receptor (RXR) isoforms in postnatal mouse (A), and embryonic day 10 chicken (B) aortic (AoV) and mitral (MV) valves.

To determine whether RA functions via classical RA receptor signaling to promote calcification, avian, murine aortic, and mitral valve explants were treated with various pharmacological RAR and RXR agonists and antagonists (Figure 3A). At moderate concentrations, it has been shown that ATRA is an elective agonist for RARs, whereas 9-cis activates both RARs and RXRs (Figure 3A).17 As for antagonists, LE540 is as an established pan-antagonist for RARs, and PA452 is known to inhibit RXR function (Figure 3A).47 To determine the efficiency of agonist and antagonist action on RAR and RXR activity, quantitative polymerase chain reaction was used to determine mRNA levels of the RAR/RXR-mediated RA target gene, RARb.45 As expected, ATRA and 9-cis significantly increase RARb expression over vehicle controls (Figure 3B). To examine relative levels of inhibition by the antagonists in this system, agonist activity was set at 100%. Using this approach, we observe that LE540 treatment inhibits ATRA- and 9-cis–mediated RAR activity to 32.95±4.93% and 38.28±5.72%, respectively (Figure 3C). For PA452, cotreatment reduces RXR activity to 53.32±9.27%, whereas treatment with both LE540 and PA452 inhibits activity to 5.11±0.05% (Figure 3D). These studies confirm the intended pharmacological activation and inhibition of RAR and RXR.

Figure 3.
Figure 3.

All-trans retinoic acid (ATRA)-mediated heart valve calcification requires retinoic acid receptor (RAR) and retinoid X receptor (RXR) activity. cE10 mitral valve explants were treated for 48 hours with indicated agonists, with or without a 4-hour antagonist pretreatment. A, Diagram depicting selectivity of RAR and RXR agonists and antagonists. B and C, Quantitative polymerase chain reaction to show changes in RARb expression (B, C) as a fold change with agonist treatments (B), and as a percent change after pretreatment with RAR (LE540) or RXR (PA452) pan-antagonists compared with ATRA and 9-cis agonists alone. D, Quantitative polymerase chain reaction analysis to show percentage changes in Sox9 expression in agonist treatment alone and pretreatment with antagonists. *P<0.05 over vehicle; #P<0.05 over agonist.

As our previous studies have shown that ATRA treatment promotes calcification via repression of Sox937, we next examined changes in Sox9 expression in response to agonist and antagonist treatments. As shown in Figure 3D, both ATRA and 9-cis significantly repress Sox9 expression in avian E10 aortic valve explants, and this repression is alleviated to levels comparable with vehicle controls when cotreated with LE540. Similarly with 9-cis, LE540 or PA452 treatments significantly prevent 9-cis-mediated Sox9 repression, although treatment with both antagonists is most effective (Figure 3D). Similar observations were observed using siRNA to target RAR, RXR, or both RAR and RXR knockdown in C3H10T1/2 cells treated with ATRA, compared with DMSO and nontargeting siRNA controls (Figure I in the online-only Data Supplement). These data suggest that both RAR and RXR are required to mediate Sox9 repression and calcification by activated RA signaling. Consistent with reduced Sox9 expression in Figure 3, von Kossa reactivity indicative of calcification is significantly increased with ATRA and 9-cis treatments of avian mitral valve explants and this phenotype is lost when cotreated with LE540, PA452, or both antagonists (Figure 4).

Figure 4.
Figure 4.

Retinoic acid treatment promotes calcific nodule formation in cE10 mitral valve explants. Compared with vehicle controls (A), von Kossa reactivity is increased after treatment with all-trans retinoic acid (ATRA) (B) and 9-cis RA (E). von Kossa reactivity is attenuated when cotreated with pharmacological antagonists (C, D, F–H). I, Quantification of von Kossa reactivity normalized to area, as indicated by Alcian blue counterstain. DMSO indicates dimethyl sulfoxide. *P<0.05 over vehicle; #P<0.05 over agonist.

RARa and RARb,g Agonist Treatment of Avian Valve Explants Represses Sox9 and Col2a1 Expression and Promotes Spp1

We and others have shown that Sox9 promotes normal cartilaginous phenotypes in heart valves through direct activation of Col2a139 and prevents ectopic bone-like calcification potentially through direct repression of Spp1.48 To examine whether this signaling pathway is downstream of RAR activity during heart valve calcification processes, gene expression analysis was performed in avian E10 and postnatal aortic valve explants treated with selective RAR agonists. To further delineate which RAR isoform might be responsible for this, specific RARa (AM580) and RARb,g (adapalene) agonists were used. As expected, both AM580 and adapelene increased RARb expression in treated avian E10 and murine postnatal aortic valve explants (Figure 5A), confirming intended targeting. Similar to ATRA treatment (Figure 3), AM580 (RARa) and adapalene (RARb,g) treatments repressed Sox9, suggesting that activity of all 3 RAR isoforms are sufficient to induce Sox9 repression. In addition to Sox9, expression of the cartilaginous marker, Col2a1, was also downregulated, whereas Spp1 associated with osteogenic processes was increased (Figure 5B and 5C). In contrast to Spp1, expression of the osteogenic transcription factor Runx2 was not significantly changed in this assay after 48-hour treatment (data not shown). These results suggest that in heart valves, activated RA signaling via RARa,b,g repress Sox9 leading to decreased Col2a1 (cartilage-like) and increased Spp1 (osteogenic).

Figure 5.
Figure 5.

Treatment with specific retinoic acid receptor (RAR) isoform agonists promotes expression of osteogenic genes at the expense of cartilaginous markers. A, Quantitative polymerase chain reaction to show fold changes in RARb expression after treatment of cE10 or postnatal mouse aortic valve (AoV) explants with RARa- (AM580) and RARb,g,-specific (Adapalene) agonists relative to vehicle controls. B and C, Quantitative polymerase chain reaction to show changes in osteogenic (Spp1) and cartilaginous (Sox9, Col2a1) gene expression after treatments. *P<0.05 over vehicle controls.

Microarray Analysis Reveals Significant Changes in Gene Expression Profiles Associated With Bone Development and ECM in Murine Aortic Heart Valves After Short-Term ATRA Treatment

To fully examine the differential gene expression changes in aortic valves in response to short-term ATRA treatment, a high throughput microarray approach was used. Compared with DMSO vehicle controls, a total of 432 probe sets were differentially expressed in ATRA-treated aortic valve explants, with 118 being downregulated and 314 increased. The 432 probe sets were ranked based on false discovery rate (<0.1) and fold change (>2), and the top 100 are listed in Table I in the online-only Data Supplement. As expected, these top 100 hits include increased mRNA transcripts associated with RA metabolism and signaling RARb (+4.76-fold), retinol binding protein 1 (rbp1) (+2.10), cytochrome P450 (Cyp26a1) (+2.37), and retinoic acid receptor responder (Rarres2) (+2.73). Of the 432 differentially expressed probe sets, 12 were randomly selected and successfully validated by quantitative polymerase chain reaction using independent cDNA samples (Table II in the online-only Data Supplement). Gene ontology analysis of the 432 probe sets altered by ATRA treatment revealed significant enrichment of genes associated with bone development and the ECM (Table). These data suggest that short-term ATRA treatment of aortic valve explants promotes calcification by activating gene expression profiles consistent to that observed in excised human calcified valves.3,5

View this table:
Table.

Gene Ontology Analysis of Microarray Data for ATRA-Treated Aortic Valve Explants Compared With DMSO Vehicle Controls Shows Enrichment of Bone Development and Extracellular Matrix Gene Programs

Discussion

In this study, we determined the effects of excess dietary vitamin A on heart valve structure and function and examined the signaling mechanisms underlying RA-induced changes in the gene expression profiles of valves. We show that long-term hypervitaminosis A in mice leads to aortic valve stenosis and leaflet calcification associated with increased osteogenic gene expression profiles in vivo. Using an established in vitro valve explant culture system, we also determined that RA-induced calcification signals through RAR and RXR, and leads to Sox9 repression and dysregulation of its target genes including decreased Col2a1 and increased Spp1. In support, gene ontology analysis of microarray findings show that gene expression probe sets associated with bone development and ECM processes are enriched in ATRA-treated murine aortic valve explants. These results imply that RA signaling must be tightly regulated in adult mice to maintain heart valve connective tissue homeostasis. Further, findings from this study suggest that excess exposure to retinoids could contribute to CAVD onset and progression in the human population.

Excess Dietary Intake of Vitamin A Promotes Valve Dysfunction in Mice

We show that increased dietary vitamin A intake in adult mice promotes CAVD phenotypes in vivo. In humans, it is estimated that 75% of people ingest more than the recommended daily allowance of vitamin A on a regular basis.16 In pregnant women, the teratogenic potential of excess vitamin A and β carotene on development of the heart in the embryo have been well established; however, less is known of the long-term effects of hypervitaminosis A on cardiac structure and function in adults. Compared with mice fed 20 IU/g of retinyl palmitate, wild-type mice receiving 10 times excess develop aortic valve stenosis as evident by increased peak pressure gradient and velocity (Figure 1E–1H). This functional defect is attributed to formation of calcific nodules on the cusp surface (Figure 1A–1B) and increased expression of osteogenic genes (Figure 1D), as commonly observed in human patients with CAVD,1 therefore suggesting that high retinoid exposure is detrimental to heart valve structure and function in mice. In humans, clinical trial studies in smokers or lung cancer patients have shown that excess retinoid exposure is also associated with cardiovascular events and even mortality, although data are conflicting, reporting positive,49,50 negative,51 or no52,53 effects in promoting cardiovascular disease. In mice, 9-cis and β carotene dietary supplements or administration of the synthetic retinoid AM80 is beneficial in the regression of atherosclerotic lesion formation in genetically susceptible mouse models of atherosclerosis.54,55 These studies suggest that excess retinoid exposure can have differential effects on the cardiovascular system that may be dependent on existing conditions, and therefore studies to determine whether dietary hypervitaminosis A accelerates pathogenesis in susceptible mouse models of CAVD would be informative.

RA Treatment Promotes Osteogenic- and Represses Cartilage-Like Processes in Adult Heart Valve Connective Tissue

Despite valve function deteriorating in mice exposed to excess dietary retinoid intake, no other overt cardiac defects were observed and myocardial contractility was comparable with controls. This suggests that in wild-type adult mice, excess dietary vitamin A does not cause overt changes in all cardiovascular structures but specifically affects connective tissue homeostasis in the valves to promote CAVD. Calcification of other systems, including the vasculature, have previously been associated with high levels of vitamin A and its derivatives.56,57 In our previous study,37 we showed that ATRA treatment promotes valve calcification via downregulation of Sox9 and mice with reduced Sox9 function develop early onset heart valve calcification in vivo.37 In these mice, calcific phenotypes are associated with increased expression of osteogenic markers and downregulation of cartilaginous genes within the valve structures.37 Similarly, in this study, our microarray analysis reveals enrichment of gene expression profiles related to bone development (Table, Figure 5) and decreased expression of cartilaginous genes (Figure 5). In other systems, ATRA treatment has been shown to promote differentiation of stem cells toward the osteogenic lineage,58,59 and negatively regulate chondrogenic phenotypes in the skeletal system as a result of reduced Sox9 activity.60 All these data suggest that ATRA-induced calcification is converging on the Sox9 pathway, and therefore the opposing effects that ATRA treatment has on cartilage and bone-like processes are likely attributed to altered regulation of Sox9 target genes leading to alleviated repression of the osteogenic glycoprotein Spp148 and lost transactivation of Col2a1.39 Our data showing that RAR and RXR are required for RA-mediated heart valve calcification (Figures 3 and 4) suggest that Sox9 repression by ATRA is regulated via a classical RA signaling pathway.61 However, using transcription factor binding site prediction software, canonical RA response elements were not identified within Sox9, and previous studies have not described direct interaction between RA receptors and Sox family members. Therefore, we anticipate that RAR/RXRs could function indirectly to regulate Sox9, potentially by positively regulating known (co)repressors of the cartilage gene program or inhibiting (co)activators of osteogenesis62–65 in this system. Alternatively, it is speculated that RA receptors cross-talk with known nuclear receptor binding partners, including vitamin D receptors, that, when depleted, similarly cause aortic valve calcification in mice.66

Hypervitaminosis A as a Model of CAVD

Defining the molecular and cellular phenotypes that contribute to the onset and progressive pathogenesis of CAVD has been challenging because of the limited number of suitable animal models available. In this study, we have identified a potentially new model of CAVD induced by increased dietary intake of vitamin A that recapitulates human disease at the functional level (Figure 1E–1H). In addition to aortic valve stenosis, positive von Kossa reactivity (Figure 1A–1B) is associated with increased expression of osteogenic genes Runx2 and Bglap (osteocalcin; Figure 1D), consistent with previous human46,67,68 and animal3,37,69,70 studies. As these increases are observed in 13-month-old mice and not in valve explants exposed to short-term ATRA treatment (data not shown), it is considered that Runx2 and Bglap serve as molecular markers of late stage disease which is consistent with human data showing similar increases in adult, but not pediatric valve disease patients.46,67 Despite increased Runx2, Spp1 (Osteopontin) expression was not altered in hypervitaminosis A mice, which is in contrast to other models of CAVD.3,37,46,70 However, high levels of Spp1 were observed in our short-term explant assays, consistent with decreased Sox9 (Figures 3 and 5), a known negative regulator.48 On the basis of these observations and data from our previous studies,37,71 we suggest that early Sox9 repression initiates pathological changes in aortic valves and promotes initial calcific nodule formation, whereas increased levels observed in hypervitaminosis A mice and end-stage human degenerative valve disease46,72 suggest potential compensatory mechanisms in response to changes in matrix composition. In addition to differential changes in osteogenic and cartilage genes, previous studies have reported active Bmp and Wnt signaling pathways in valve and vascular calcification.69,70,73,74 By microarray analysis, Bmp2 and Smad3 were increased in short-term ATRA-treated explants; however, changes in pSmad1/5/8 were not observed in our in vivo model (data not shown). Furthermore, expression of b-catenin or Wnt-associated pathways identified from Wikipathways analyses was not significantly altered, therefore suggesting that canonical bone morphogenetic protein and Wnt signaling is not active during late stages of pathogenesis in this mouse model. Collectively, these data suggest that hypervitaminosis A mice recapitulate functional and many molecular phenotypes of human and animal models of CAVD. Further, this study supports work from others identifying early and late markers of disease pathogenesis that may be important for improving diagnosis and therapeutic intervention. Further, these studies highlight the complex, multifactorial nature of CAVD pathogenesis.

Summary and Clinical Perspectives

CAVD was once considered a passive wear and tear disease most common in the aging population; however, more recent work has described it as an actively regulated process characterized by bone-like phenotypes.1 CAVD onset and progression has been associated with several genetic factors that underlie congenital valve malformations that increase susceptibility to calcification later in life. In addition, several clinical risk factors have been reported, including older age, hypertension, serum lipoprotein levels, and smoking,1,8 and although these can be attributed to genetic alterations, habitual lifestyles may also play a role. In this study, we have identified that long-term dietary intake of vitamin A results in aortic valve stenosis and leaflet calcification attributed to RAR/RXR-dependent repression of Sox9. These studies suggest that patients exposed to retinol-based therapies or dietary hypervitaminosis A may be at an increased risk of developing CAVD. Vitamin A is found in a variety of food sources, and the effects of excess supplementation by pregnant women on the developing embryo have been well described.16 However, the adverse effects of consuming large doses by healthy adults have been less well studied. Hypervitaminosis A induced by dietary intake may not be highly prevalent in developed countries; however, high retinol levels are more common in people ingesting dietary supplements as a beneficial antioxidant or in patients receiving retinol-based pharmaceuticals, including Accutane and Tegison.16 At present, CAVD is largely diagnosed from functional analyses, and biomarkers to indicate the clinical value of CAVD pathogenesis remain unknown. On the basis of this current study, retinol levels predicting CAVD susceptibility could improve risk stratification and help determine a therapeutic window to improve patient outcome.

Acknowledgments

We thank Blair Austin, Agata Levay, and Ge Tao for technical assistance and Dr T. Michael Underhill for sharing reagents. In addition, we thank Dr David Willoughby (Ocean Ridge Biosciences, LLC) for performing the microarray study.

Sources of Funding

This work was supported by National Institutes of Health grant R01-HL091878 (to J.L.) and the Research Institute at Nationwide Children’s Hospital.

Disclosures

None.

Footnotes

  • Received August 30, 2012.
  • Accepted November 3, 2012.

References

  1. 1.↵
    1. Rajamannan NM,
    2. Evans FJ,
    3. Aikawa E,
    4. Grande-Allen KJ,
    5. Demer LL,
    6. Heistad DD,
    7. Simmons CA,
    8. Masters KS,
    9. Mathieu P,
    10. O’Brien KD,
    11. Schoen FJ,
    12. Towler DA,
    13. Yoganathan AP,
    14. Otto CM
    . Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation. 2011;124:1783–1791.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Lincoln J,
    2. Yutzey KE
    . Molecular and developmental mechanisms of congenital heart valve disease. Birth Defects Res Part A Clin Mol Teratol. 2011;91:526–534.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Cheek JD,
    2. Wirrig EE,
    3. Alfieri CM,
    4. James JF,
    5. Yutzey KE
    . Differential activation of valvulogenic, chondrogenic, and osteogenic pathways in mouse models of myxomatous and calcific aortic valve disease. J Mol Cell Cardiol. 2012;52:689–700.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Wirrig EE,
    2. Snarr BS,
    3. Chintalapudi MR,
    4. O’neal JL,
    5. Phelps AL,
    6. Barth JL,
    7. Fresco VM,
    8. Kern CB,
    9. Mjaatvedt CH,
    10. Toole BP,
    11. Hoffman S,
    12. Trusk TC,
    13. Argraves WS,
    14. Wessels A
    . Cartilage link protein 1 (Crtl1), an extracellular matrix component playing an important role in heart development. Dev Biol. 2007;310:291–303.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Rajamannan NM,
    2. Gersh B,
    3. Bonow RO
    . Calcific aortic stenosis: from bench to the bedside–emerging clinical and cellular concepts. Heart. 2003;89:801–805.
    OpenUrlFREE Full Text
  6. 6.↵
    1. Beckmann E,
    2. Grau JB,
    3. Sainger R,
    4. Poggio P,
    5. Ferrari G
    . Insights into the use of biomarkers in calcific aortic valve disease. J Heart Valve Dis. 2010;19:441–452.
    OpenUrlPubMed
  7. 7.↵
    1. Garg V,
    2. Muth AN,
    3. Ransom JF,
    4. Schluterman MK,
    5. Barnes R,
    6. King IN,
    7. Grossfeld PD,
    8. Srivastava D
    . Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437:270–274.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Freeman RV,
    2. Otto CM
    . Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005;111:3316–3326.
    OpenUrlFREE Full Text
  9. 9.↵
    1. Mohler ER 3rd.,
    2. Wang H,
    3. Medenilla E,
    4. Scott C
    . Effect of statin treatment on aortic valve and coronary artery calcification. J Heart Valve Dis. 2007;16:378–386.
    OpenUrlPubMed
  10. 10.↵
    1. Nus M,
    2. MacGrogan D,
    3. Martínez-Poveda B,
    4. Benito Y,
    5. Casanova JC,
    6. Fernández-Avilés F,
    7. Bermejo J,
    8. de la Pompa JL
    . Diet-induced aortic valve disease in mice haploinsufficient for the Notch pathway effector RBPJK/CSL. Arterioscler Thromb Vasc Biol. 2011;31:1580–1588.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Barrick CJ,
    2. Roberts RB,
    3. Rojas M,
    4. Rajamannan NM,
    5. Suitt CB,
    6. O’Brien KD,
    7. Smyth SS,
    8. Threadgill DW
    . Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice. Am J Physiol Heart Circ Physiol. 2009;297:H65–H75.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Nigam V,
    2. Srivastava D
    . Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol. 2009;47:828–834.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Aikawa E,
    2. Aikawa M,
    3. Libby P,
    4. Figueiredo JL,
    5. Rusanescu G,
    6. Iwamoto Y,
    7. Fukuda D,
    8. Kohler RH,
    9. Shi GP,
    10. Jaffer FA,
    11. Weissleder R
    . Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation. 2009;119:1785–1794.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Schmidt N,
    2. Brandsch C,
    3. Kühne H,
    4. Thiele A,
    5. Hirche F,
    6. Stangl GI
    . Vitamin D receptor deficiency and low vitamin D diet stimulate aortic calcification and osteogenic key factor expression in mice. PLoS ONE. 2012;7:e35316.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Drolet MC,
    2. Roussel E,
    3. Deshaies Y,
    4. Couet J,
    5. Arsenault M
    . A high fat/high carbohydrate diet induces aortic valve disease in C57BL/6J mice. J Am Coll Cardiol. 2006;47:850–855.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Duerbeck NB,
    2. Dowling DD
    . Vitamin A: too much of a good thing? Obstet Gynecol Surv. 2012;67:122–128.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Theodosiou M,
    2. Laudet V,
    3. Schubert M
    . From carrot to clinic: an overview of the retinoic acid signaling pathway. Cell Mol Life Sci. 2010;67:1423–1445.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Rochette-Egly C,
    2. Germain P
    . Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs). Nucl Recept Signal. 2009;7:e005.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Ziouzenkova O,
    2. Plutzky J
    . Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR-RXR complex. FEBS Lett. 2008;582:32–38.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Vermot J,
    2. Niederreither K,
    3. Garnier JM,
    4. Chambon P,
    5. Dollé P
    . Decreased embryonic retinoic acid synthesis results in a DiGeorge syndrome phenotype in newborn mice. Proc Natl Acad Sci USA. 2003;100:1763–1768.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Ryckebüsch L,
    2. Bertrand N,
    3. Mesbah K,
    4. Bajolle F,
    5. Niederreither K,
    6. Kelly RG,
    7. Zaffran S
    . Decreased levels of embryonic retinoic acid synthesis accelerate recovery from arterial growth delay in a mouse model of DiGeorge syndrome. Circ Res. 2010;106:686–694.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Sakabe M,
    2. Kokubo H,
    3. Nakajima Y,
    4. Saga Y
    . Ectopic retinoic acid signaling affects outflow tract cushion development through suppression of the myocardial Tbx2-Tgfβ2 pathway. Development. 2012;139:385–395.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Gruber PJ,
    2. Kubalak SW,
    3. Pexieder T,
    4. Sucov HM,
    5. Evans RM,
    6. Chien KR
    . RXR alpha deficiency confers genetic susceptibility for aortic sac, conotruncal, atrioventricular cushion, and ventricular muscle defects in mice. J Clin Invest. 1996;98:1332–1343.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Sucov HM,
    2. Dyson E,
    3. Gumeringer CL,
    4. Price J,
    5. Chien KR,
    6. Evans RM
    . RXR alpha mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. Genes Dev. 1994;8:1007–1018.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Pavan M,
    2. Ruiz VF,
    3. Silva FA,
    4. Sobreira TJ,
    5. Cravo RM,
    6. Vasconcelos M,
    7. Marques LP,
    8. Mesquita SM,
    9. Krieger JE,
    10. Lopes AA,
    11. Oliveira PS,
    12. Pereira AC,
    13. Xavier-Neto J
    . ALDH1A2 (RALDH2) genetic variation in human congenital heart disease. BMC Med Genet. 2009;10:113.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Ryckebusch L,
    2. Wang Z,
    3. Bertrand N,
    4. Lin SC,
    5. Chi X,
    6. Schwartz R,
    7. Zaffran S,
    8. Niederreither K
    . Retinoic acid deficiency alters second heart field formation. Proc Natl Acad Sci USA. 2008;105:2913–2918.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Jiang X,
    2. Choudhary B,
    3. Merki E,
    4. Chien KR,
    5. Maxson RE,
    6. Sucov HM
    . Normal fate and altered function of the cardiac neural crest cell lineage in retinoic acid receptor mutant embryos. Mech Dev. 2002;117:115–122.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Keyte A,
    2. Hutson MR
    . The neural crest in cardiac congenital anomalies. Differentiation. 2012;84:25–40.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Brade T,
    2. Kumar S,
    3. Cunningham TJ,
    4. Chatzi C,
    5. Zhao X,
    6. Cavallero S,
    7. Li P,
    8. Sucov HM,
    9. Ruiz-Lozano P,
    10. Duester G
    . Retinoic acid stimulates myocardial expansion by induction of hepatic erythropoietin which activates epicardial Igf2. Development. 2011;138:139–148.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Tran CM,
    2. Sucov HM
    . The RXRalpha gene functions in a non-cell-autonomous manner during mouse cardiac morphogenesis. Development. 1998;125:1951–1956.
    OpenUrlAbstract
  31. 31.↵
    1. Lin SC,
    2. Dollé P,
    3. Ryckebüsch L,
    4. Noseda M,
    5. Zaffran S,
    6. Schneider MD,
    7. Niederreither K
    . Endogenous retinoic acid regulates cardiac progenitor differentiation. Proc Natl Acad Sci USA. 2010;107:9234–9239.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Sorrell MR,
    2. Waxman JS
    . Restraint of Fgf8 signaling by retinoic acid signaling is required for proper heart and forelimb formation. Dev Biol. 2011;358:44–55.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Pérez-Pomares JM,
    2. Phelps A,
    3. Sedmerova M,
    4. Carmona R,
    5. González-Iriarte M,
    6. Muñoz-Chápuli R,
    7. Wessels A
    . Experimental studies on the spatiotemporal expression of WT1 and RALDH2 in the embryonic avian heart: a model for the regulation of myocardial and valvuloseptal development by epicardially derived cells (EPDCs). Dev Biol. 2002;247:307–326.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. von Gise A,
    2. Zhou B,
    3. Honor LB,
    4. Ma Q,
    5. Petryk A,
    6. Pu WT
    . WT1 regulates epicardial epithelial to mesenchymal transition through β-catenin and retinoic acid signaling pathways. Dev Biol. 2011;356:421–431.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Braitsch CM,
    2. Combs MD,
    3. Quaggin SE,
    4. Yutzey KE
    . Pod1/Tcf21 is regulated by retinoic acid signaling and inhibits differentiation of epicardium-derived cells into smooth muscle in the developing heart. Dev Biol. 2012;368:345–357.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Niederreither K,
    2. Vermot J,
    3. Messaddeq N,
    4. Schuhbaur B,
    5. Chambon P,
    6. Dollé P
    . Embryonic retinoic acid synthesis is essential for heart morphogenesis in the mouse. Development. 2001;128:1019–1031.
    OpenUrlAbstract
  37. 37.↵
    1. Peacock JD,
    2. Levay AK,
    3. Gillaspie DB,
    4. Tao G,
    5. Lincoln J
    . Reduced sox9 function promotes heart valve calcification phenotypes in vivo. Circ Res. 2010;106:712–719.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Lincoln J,
    2. Lange AW,
    3. Yutzey KE
    . Hearts and bones: shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development. Dev Biol. 2006;294:292–302.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Ng LJ,
    2. Wheatley S,
    3. Muscat GE,
    4. Conway-Campbell J,
    5. Bowles J,
    6. Wright E,
    7. Bell DM,
    8. Tam PP,
    9. Cheah KS,
    10. Koopman P
    . SOX9 binds DNA, activates transcription, and coexpresses with type II collagen during chondrogenesis in the mouse. Dev Biol. 1997;183:108–121.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Levay AK,
    2. Peacock JD,
    3. Lu Y,
    4. Koch M,
    5. Hinton RB Jr.,
    6. Kadler KE,
    7. Lincoln J
    . Scleraxis is required for cell lineage differentiation and extracellular matrix remodeling during murine heart valve formation in vivo. Circ Res. 2008;103:948–956.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Schuster GU,
    2. Kenyon NJ,
    3. Stephensen CB
    . Vitamin A deficiency decreases and high dietary vitamin A increases disease severity in the mouse model of asthma. J Immunol. 2008;180:1834–1842.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Sagazio A,
    2. Piantedosi R,
    3. Alba M,
    4. Blaner WS,
    5. Salvatori R
    . Vitamin A deficiency does not influence longitudinal growth in mice. Nutrition. 2007;23:483–488.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Kitaoka K,
    2. Hattori A,
    3. Chikahisa S,
    4. Miyamoto K,
    5. Nakaya Y,
    6. Sei H
    . Vitamin A deficiency induces a decrease in EEG delta power during sleep in mice. Brain Res. 2007;1150:121–130.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Kuwata T,
    2. Wang IM,
    3. Tamura T,
    4. Ponnamperuma RM,
    5. Levine R,
    6. Holmes KL,
    7. Morse HC,
    8. De Luca LM,
    9. Ozato K
    . Vitamin A deficiency in mice causes a systemic expansion of myeloid cells. Blood. 2000;95:3349–3356.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Aggarwal S,
    2. Kim SW,
    3. Cheon K,
    4. Tabassam FH,
    5. Yoon JH,
    6. Koo JS
    . Nonclassical action of retinoic acid on the activation of the cAMP response element-binding protein in normal human bronchial epithelial cells. Mol Biol Cell. 2006;17:566–575.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Caira FC,
    2. Stock SR,
    3. Gleason TG,
    4. McGee EC,
    5. Huang J,
    6. Bonow RO,
    7. Spelsberg TC,
    8. McCarthy PM,
    9. Rahimtoola SH,
    10. Rajamannan NM
    . Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006;47:1707–1712.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Umemiya H,
    2. Fukasawa H,
    3. Ebisawa M,
    4. Eyrolles L,
    5. Kawachi E,
    6. Eisenmann G,
    7. Gronemeyer H,
    8. Hashimoto Y,
    9. Shudo K,
    10. Kagechika H
    . Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. J Med Chem. 1997;40:4222–4234.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Peacock JD,
    2. Huk DJ,
    3. Ediriweera HN,
    4. Lincoln J
    . Sox9 transcriptionally represses Spp1 to prevent matrix mineralization in maturing heart valves and chondrocytes. PLoS ONE. 2011;6:e26769.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Omenn GS,
    2. Goodman GE,
    3. Thornquist MD,
    4. Balmes J,
    5. Cullen MR,
    6. Glass A,
    7. Keogh JP,
    8. Meyskens FL,
    9. Valanis B,
    10. Williams JH,
    11. Barnhart S,
    12. Hammar S
    . Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150–1155.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Rapola JM,
    2. Virtamo J,
    3. Ripatti S,
    4. Huttunen JK,
    5. Albanes D,
    6. Taylor PR,
    7. Heinonen OP
    . Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 1997;349:1715–1720.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Street DA,
    2. Comstock GW,
    3. Salkeld RM,
    4. Schüep W,
    5. Klag MJ
    . Serum antioxidants and myocardial infarction. Are low levels of carotenoids and alpha-tocopherol risk factors for myocardial infarction? Circulation. 1994;90:1154–1161.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    1. Hennekens CH,
    2. Buring JE,
    3. Manson JE,
    4. Stampfer M,
    5. Rosner B,
    6. Cook NR,
    7. Belanger C,
    8. LaMotte F,
    9. Gaziano JM,
    10. Ridker PM,
    11. Willett W,
    12. Peto R
    . Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145–1149.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Lee IM,
    2. Cook NR,
    3. Manson JE,
    4. Buring JE,
    5. Hennekens CH
    . Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women’s Health Study. J Natl Cancer Inst. 1999;91:2102–2106.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    1. Takeda N,
    2. Manabe I,
    3. Shindo T,
    4. Iwata H,
    5. Iimuro S,
    6. Kagechika H,
    7. Shudo K,
    8. Nagai R
    . Synthetic retinoid Am80 reduces scavenger receptor expression and atherosclerosis in mice by inhibiting IL-6. Arterioscler Thromb Vasc Biol. 2006;26:1177–1183.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Harari A,
    2. Harats D,
    3. Marko D,
    4. Cohen H,
    5. Barshack I,
    6. Kamari Y,
    7. Gonen A,
    8. Gerber Y,
    9. Ben-Amotz A,
    10. Shaish A
    . A 9-cis beta-carotene-enriched diet inhibits atherogenesis and fatty liver formation in LDL receptor knockout mice. J Nutr. 2008;138:1923–1930.
    OpenUrlAbstract/FREE Full Text
  56. 56.↵
    1. Strebel RF,
    2. Girerd RJ,
    3. Wagner BM
    . Cardiovascular calcification in rats with hypervitaminosis A. Arch Pathol. 1969;87:290–297.
    OpenUrlPubMed
  57. 57.↵
    1. Jacobson A,
    2. Johansson S,
    3. Branting M,
    4. Melhus H
    . Vitamin A differentially regulates RANKL and OPG expression in human osteoblasts. Biochem Biophys Res Commun. 2004;322:162–167.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Roberts SJ,
    2. Chen Y,
    3. Moesen M,
    4. Schrooten J,
    5. Luyten FP
    . Enhancement of osteogenic gene expression for the differentiation of human periosteal derived cells. Stem Cell Res. 2011;7:137–144.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Luther G,
    2. Wagner ER,
    3. Zhu G,
    4. et al
    . BMP-9 induced osteogenic differentiation of mesenchymal stem cells: molecular mechanism and therapeutic potential. Curr Gene Ther. 2011;11:229–240.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. Weston AD,
    2. Chandraratna RA,
    3. Torchia J,
    4. Underhill TM
    . Requirement for RAR-mediated gene repression in skeletal progenitor differentiation. J Cell Biol. 2002;158:39–51.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Rhee EJ,
    2. Nallamshetty S,
    3. Plutzky J
    . Retinoid metabolism and its effects on the vasculature. Biochim Biophys Acta. 2012;1821:230–240.
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Kawakami Y,
    2. Tsuda M,
    3. Takahashi S,
    4. Taniguchi N,
    5. Esteban CR,
    6. Zemmyo M,
    7. Furumatsu T,
    8. Lotz M,
    9. Izpisúa Belmonte JC,
    10. Asahara H
    . Transcriptional coactivator PGC-1alpha regulates chondrogenesis via association with Sox9. Proc Natl Acad Sci USA. 2005;102:2414–2419.
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Semba I,
    2. Nonaka K,
    3. Takahashi I,
    4. Takahashi K,
    5. Dashner R,
    6. Shum L,
    7. Nuckolls GH,
    8. Slavkin HC
    . Positionally-dependent chondrogenesis induced by BMP4 is co-regulated by Sox9 and Msx2. Dev Dyn. 2000;217:401–414.
    OpenUrlCrossRefPubMed
  64. 64.↵
    1. Furumatsu T,
    2. Tsuda M,
    3. Yoshida K,
    4. Taniguchi N,
    5. Ito T,
    6. Hashimoto M,
    7. Ito T,
    8. Asahara H
    . Sox9 and p300 cooperatively regulate chromatin-mediated transcription. J Biol Chem. 2005;280:35203–35208.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Rau MJ,
    2. Fischer S,
    3. Neumann CJ
    . Zebrafish Trap230/Med12 is required as a coactivator for Sox9-dependent neural crest, cartilage and ear development. Dev Biol. 2006;296:83–93.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Schmidt RJ,
    2. Tancredi DJ,
    3. Ozonoff S,
    4. Hansen RL,
    5. Hartiala J,
    6. Allayee H,
    7. Schmidt LC,
    8. Tassone F,
    9. Hertz-Picciotto I
    . Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (CHildhood Autism Risks from Genetics and Environment) case-control study. Am J Clin Nutr. 2012;96:80–89.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Wirrig EE,
    2. Hinton RB,
    3. Yutzey KE
    . Differential expression of cartilage and bone-related proteins in pediatric and adult diseased aortic valves. J Mol Cell Cardiol. 2011;50:561–569.
    OpenUrlCrossRefPubMed
  68. 68.↵
    1. Yang X,
    2. Meng X,
    3. Su X,
    4. Mauchley DC,
    5. Ao L,
    6. Cleveland JC Jr.,
    7. Fullerton DA
    . Bone morphogenic protein 2 induces Runx2 and osteopontin expression in human aortic valve interstitial cells: role of Smad1 and extracellular signal-regulated kinase ½. J Thorac Cardiovasc Surg. 2009;138:1008–1015.
    OpenUrlCrossRefPubMed
  69. 69.↵
    1. Rajamannan NM
    . The role of Lrp5/6 in cardiac valve disease: experimental hypercholesterolemia in the ApoE-/- /Lrp5-/- mice. J Cell Biochem. 2011;112:2987–2991.
    OpenUrlCrossRefPubMed
  70. 70.↵
    1. Rajamannan NM,
    2. Subramaniam M,
    3. Caira F,
    4. Stock SR,
    5. Spelsberg TC
    . Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation. 2005;112(suppl 9):I229–I234.
    OpenUrlPubMed
  71. 71.↵
    1. Lincoln J,
    2. Kist R,
    3. Scherer G,
    4. Yutzey KE
    . Sox9 is required for precursor cell expansion and extracellular matrix organization during mouse heart valve development. Dev Biol. 2007;305:120–132.
    OpenUrlCrossRefPubMed
  72. 72.↵
    1. Wirrig EE,
    2. Yutzey KE
    . Transcriptional regulation of heart valve development and disease. Cardiovasc Pathol. 2011;20:162–167.
    OpenUrlCrossRefPubMed
  73. 73.↵
    1. Beazley KE,
    2. Deasey S,
    3. Lima F,
    4. Nurminskaya MV
    . Transglutaminase 2-mediated activation of β-catenin signaling has a critical role in warfarin-induced vascular calcification. Arterioscler Thromb Vasc Biol. 2012;32:123–130.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    1. Alfieri CM,
    2. Cheek J,
    3. Chakraborty S,
    4. Yutzey KE
    . Wnt signaling in heart valve development and osteogenic gene induction. Dev Biol. 2010;338:127–135.
    OpenUrlCrossRefPubMed
View Abstract

This Issue

Jump to

Article Tools

Share this Article

  • Email
  • Increased Dietary Intake of Vitamin A Promotes Aortic Valve Calcification In Vivo
    Danielle J. Huk, Harriet L. Hammond, Hiroyuki Kegechika and Joy Lincoln
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33:285-293, originally published January 16, 2013
    https://doi.org/10.1161/ATVBAHA.112.300388
    Permalink:
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects